Innerva Pharmaceuticals is developing a first-in-class neuromodulator that targets PIEZO2 ion channels in ocular surface nerve endings to alleviate ocular surface pain. This novel approach addresses the significant unmet need for effective treatments in patients suffering from chronic ocular discomfort.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for chronic ocular surface pain often fail to provide adequate relief, leaving patients with persistent discomfort and limited therapeutic options. There is a significant unmet need for novel and effective therapies that specifically target the underlying mechanisms of ocular pain.
Solution
Innerva Pharmaceuticals is developing a first-in-class neuromodulator designed to alleviate ocular surface pain by selectively blocking PIEZO2 ion channels located on ocular surface nerve endings. This innovative approach aims to reduce pain signaling at the source, offering a targeted solution for patients suffering from chronic ocular discomfort. By pioneering the pharmacological blockade of PIEZO2, Innerva seeks to provide a novel therapeutic option that addresses the limitations of existing treatments. The company's research and development efforts are focused on creating therapies that can improve the quality of life for individuals affected by ocular pain.
Target Audience
The primary target audience includes patients suffering from chronic ocular surface pain and ophthalmologists seeking more effective treatment options for their patients.
Features
- Selective blockade of PIEZO2 ion channels in ocular surface nerve endings
- First-in-class neuromodulator mechanism of action
- Targeted pain relief for chronic ocular discomfort